EGFR and lung cancer: Importantly, in contrast to the preferential activity of chemotherapy against differentiated cells, erlotinib cytotoxicity was even more marked against the LCSCs than against their differentiated counterpart both in vitro and in xenografts, acquiring a great value as a CSC-directed therapeutic drug in the context of WT-EGFR lung cancers.